PPT-Brentuximab
Author : briana-ranney | Published Date : 2017-08-28
Vedotin Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant Catherine Diefenbach MD Assistant Professor of
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Brentuximab" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Brentuximab: Transcript
Vedotin Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant Catherine Diefenbach MD Assistant Professor of Medicine NYU Perlmutter Cancer Center NYU . How and When Should it be Used in B and T cell Lymphomas. Ranjana. . Advani. MD. Professor of Medicine. Saul Rosenberg Professor of Lymphoma. Stanford University. Lymphoma and Myeloma 2014. International Congress on Hematologic Malignancies . Hodgkin Lymphoma. Program Objectives. Brentuximab Vedotin in Hodgkin Lymphoma. Brentuximab Vedotin in Patients With R/R HL. Brentuximab Vedotin: Adverse Events . Nivolumab in Relapsed/Refractory HL. Pembrolizumab in Relapsed/Refractory HL. in CR with . Brentuximab. :. Koen van Besien, MD, PhD. Weill Cornell Medical College. Recurrent HL after . Autotransplant. in CR with . Brentuximab. :. ALLO. Koen van Besien, MD, PhD. Weill Cornell Medical College. T. ransplant . in CR on . B. rentuximab. . V. edotin. : . Allo. . Transplant . or . Maintenance . T. herapy. ?. Anas Younes, M.D.. Memorial Sloan Kettering Cancer Center. Overall Survival. <1990 median 1.9 yrs. Supported by educational grants from AbbVie, AstraZeneca, Gilead Sciences Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, and . Seattle Genetics.. CCO Independent Conference Highlights*.
Download Document
Here is the link to download the presentation.
"Brentuximab"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
